Amendment to Consulting Agreement between Momenta Pharmaceuticals, Inc. and Dr. Ram Sasisekharan (July 12, 2004)

Summary

This letter agreement extends the consulting arrangement between Momenta Pharmaceuticals, Inc. and Dr. Ram Sasisekharan for one additional year, from August 16, 2004, to August 15, 2005, under the same terms and compensation as the original agreement. Dr. Sasisekharan confirms he has not been debarred by the FDA and is not under consideration for debarment. Both parties must sign the letter to confirm their agreement to the extension.

EX-10.1 2 a04-13269_1ex10d1.htm EX-10.1

Exhibit 10.1

 

July 12, 2004

 

Dr. Ram Sasisekharan

2130 Massachusetts Avenue, 7B

Cambridge, Massachusetts 02139

 

Dear Ram:

 

Reference is made to the Consulting Agreement between Momenta Pharmaceuticals, Inc. (formerly Mimeon, Inc.) and you dated August 16, 2001, as amended by letter agreement dated August 1, 2003 (the “Agreement”).  Capitalized terms used herein and not otherwise defined shall have the meanings given such terms in the Agreement.

 

Pursuant to Section 1 of the Agreement, Company and Consultant hereby agree to extend the term of the Agreement for one additional year, from August 16, 2004 through August 15, 2005, upon the same terms and conditions, including, without limitation, those governing compensation, as are set forth in the Agreement.

 

Consultant hereby represents that Consultant has not been debarred, and to the best of Consultant’s knowledge, is not under consideration to be debarred, by the Food and Drug Administration from working in or providing services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992.

 

If the foregoing is in conformity with your understanding, please sign both copies of this letter agreement and return one fully-executed copy to me.

 

Very truly yours,

 

/s/ Alan L. Crane

 

Alan L. Crane

Chief Executive Officer

 

Agreed and accepted:

 

/s/ Ram Sasisekharan

 

Ram Sasisekharan